NLSP H1 2025 Earnings Results — NLS Pharmaceutics Ltd. Ordinary Shares
XNAS · Healthcare · Biotechnology
Updated
When is NLSP's next earnings date?
NLS Pharmaceutics Ltd. Ordinary Shares (NLSP) has not announced its next earnings date yet. Its most recent earnings report was on Monday, October 6, 2025.
How did NLSP do in its last earnings report?
In its most recent report on Oct 6, 2025 (H1 2025), NLS Pharmaceutics Ltd. Ordinary Shares posted EPS of -$1.05. Revenue was $0. The stock's 1-day post-earnings move was -3.8%.
How much does NLSP stock move after earnings?
NLSP beat EPS estimates in 1 of its last 1 reported quarter. Over the last 5 reports the stock moved an average of 4.9% (up or down) in the day after earnings.
About NLS Pharmaceutics Ltd. Ordinary Shares
NLS Pharmaceutics Ltd a clinical-stage biopharmaceutical company focused on the discovery and development of inventive therapies for patients with rare and complex CNS disorders with unmet medical needs. Its compound, mazindol, a triple monoamine reuptake inhibitor and partial orexin receptor 2 agonist, in a proprietary ER formulation, is being developed for the treatment of narcolepsy, IH (follow-on indication), and potentially ADHD (back-up indication). Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2025-10-06 | H1 2025 | — | -1.05 | — | $0 | — | -3.76% | -11.78% | — |
| 2024-10-18 | H1 2024 | — | -1.94 | — | $0 | — | -10.19% | -21.13% | -38.49% |
| 2024-05-15 | FY 2023 | — | -0.32 | — | $0 | — | +2.33% | +9.52% | -21.99% |
| 2023-12-06 | H1 2023 | — | -0.20 | — | $0 | — | -5.08% | -14.26% | +2.02% |
| 2023-05-05 | FY 2022 | — | -0.84 | — | $0 | — | -2.90% | -24.64% | -31.10% |
| 2022-10-11 | — | -17.60 | — | — | — | — | — | — | |
| 2022-03-24 | -13.80 | -12.40 | — | — | ✅ Beat | — | — | — | |
| 2021-09-28 | — | -0.42 | — | — | — | — | — | — |
Showing last 8 quarters.